Engineered natural killer cells expressing chimeric antigen receptors (CAR)—a promising approach in tumor immunotherapy
Cell gene therapy is a promising approach for the treatment of cancers resistant to conventional therapy with cytostatic drugs and monoclonal antibodies. In particular, the use of genetically engineered immune cells showed remarkable results in the treatment of patients with leukemia and lymphoma, but there are still undeniable limitations of this approach. In the paper “Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity” (1). Li et al. provide interesting possibilities to enable improved anti-tumor activity and gives potentially concepts to overcome the limits especially in the field of solid tumors.